Glenmark Pharmaceuticals Ltd News

Glenmark Pharmaceuticals Q1 result: PAT at ₹482.83 cr, revenue at ₹4,018 cr

Glenmark Pharmaceuticals on Friday reported a multi-fold increase in consolidated profit after tax at Rs 482.83 crore in the first quarter ended June 30, 2026, on the back of strong revenue growth and low base effect. The company had posted a consolidated profit after tax (PAT) of Rs 46.97 crore in the corresponding quarter last fiscal, Glenmark Pharmaceuticals said in a regulatory filing. In the year-ago quarter, the company had an exceptional item outgo of Rs 323.23 crore. Consolidated total revenue from operations in the first quarter this fiscal stood at Rs 4,018.48 crore as compared to Rs 3,264.44 crore in the same period a year ago, the filing said. Total expenses in the quarter under review were higher at Rs 3,440.86 crore as compared to Rs 2,872.07 crore, the company said. "We have started FY2027 with broad-based growth across our key markets, reflecting strong execution and the resilience of our business. "India continued to outperform the market, North America delivered

Stocks to buy: TVS Motor among 3 stock ideas from Ajit Mishra; here's why

Technically, the Nifty has reclaimed the immediate resistance zone formed by the 20-day and 100-day DEMA, indicating an improvement in the near-term technical setup.

Glenmark, Biocon, Aurobindo slip 3% on Trump's generic drug tariff plan

The US President Donald Trump announced a proposal to impose phased tariff (up to 200%) regime on imported generic medicines aimed at encouraging pharmaceutical manufacturing within the United States.

Glenmark Pharma jumps over 2% on launch of Olanzapine single-dose vial

Glenmark Pharma stock advanced over 2% in Monday's intra-day trade, after the company's US arm announced the launch of Olanzapine single-dose vial.

Glenmark launches generic schizophrenia, bipolar disorder drug in US

Glenmark Pharmaceuticals on Monday announced the launch of the generic version of Olanzapine injection, indicated for treatment of schizophrenia and bipolar disorder, in the US. The company's arm Glenmark Pharmaceuticals Inc, USA has launched Olanzapine for injection of strength 10 mg/vial, single-dose vial, Glenmark said in a regulatory filing. The company's Olanzapine for injection is bioequivalent and therapeutically equivalent to the reference listed drug, Zyprexa intramuscular injection 10 mg/vial, of Cheplapharm Registration GmbH, it added. "The launch of Olanzapine for Injection underscores our strategic focus on growing a robust injectables portfolio and strengthening our presence within the institutional channel," Glenmark President & Business Head, North America, Marc Kikuchi said. Citing IQVIA sales data for the 12-month period ended May 2026, Glenmark said the Zyprexa intramuscular injection market achieved annual sales of approximately USD 25.4 million.

Nifty Pharma index up 2%; Dr Reddy's, Ajanta, Ipca, Cipla surge up to 5%

In the past seven trading days, the Nifty Pharma index outperformed the market by soaring 5.4 per cent, as compared to 0.1 per cent decline in the Nifty 50.

Glenmark launches Lacosamide injection in US, targets $15.2 million market

Company's Lacosamide Injection, available in single-dose vials, is a generic version of UCB's Vimpat; reference drug recorded annual sales of $15.2 million

Stocks to watch today: Bosch, ABCL, Whirlpool India, Jubilant Foodworks

Stocks to Watch today, May 21, 2026: Bosch, Whirlpool of India, Aditya Birla Capital, and Reliance Industries are some of the key stocks to watch today

Sun Pharma, Dr Reddy's Labs, Onesource: Nifty Pharma rallies 3%; details

Among others, Sun Pharma was the top gainer up over 7 per cent, followed by Gland Pharma, Alkem Laboratories, Zydus Lifesciences and Wockhardt up over 2 per cent

Nifty eyes 24,600; SBI, Glenmark Pharma, Tata Power on analyst radar

Stocks to buy: Ajit Mishra of Religare Broking recommends buying the shares of State Bank of India, Glenmark Pharma, and Tata Power today

Glenmark receives USFDA approval for generic progesterone vaginal inserts

Glenmark Pharmaceuticals on Thursday said it has received final approval from the US health regulator for its generic version of progesterone vaginal inserts used in fertility treatments. The approval by the US Food and Drug Administration (USFDA) is for progesterone vaginal inserts of strength 100 mg, Glenmark Pharmaceuticals Ltd said in a regulatory filing. It has been determined by the USFDA to be bioequivalent and therapeutically equivalent to the reference listed drug, Endometrin vaginal inserts, 100 mg of Ferring Pharmaceuticals Inc, it added. Glenmark's progesterone vaginal inserts 100 mg will be distributed in the US by Glenmark Pharmaceuticals Inc, USA, the company said. "This approval for Progesterone Vaginal Inserts, 100 mg marks an important addition to our business and reinforces our focus on addressing patient needs in women's healthcare," Glenmark President & Business Head, North America, Marc Kikuchi said. Citing IQVIA sales data for the 12 months ended February ..

Stocks to Watch today: Acme Solar, Indian Oil, Power Grid, Glenmark Pharma

Stocks to Watch today, April 2, 2026: Lupin, Inox Clean Energy, Latent View Analytics, Jubilant FoodWorks, and Lemon Tree Hotels are among the top stocks to watch during today's trading session

Glenmark takes direct control of Ryaltris sales in US from April 2026

Glenmark will directly manage Ryaltris sales in the US from April 2026, strengthening its innovation-led portfolio and expanding its commercial presence in the market

Astral, Glenmark, Nalco among high conviction F&O bets in April: Systematix

The futures & options market positioning reflects heavy short build-up, creating conditions for sharp but temporary short-covering rallies, says Systematix Institutional Equities.

Analyst suggests Nifty strategy; bets on BSE, Delhivery, Glenmark Pharma

Ajit Mishra of Religare Broking recommends buying the shares of BSE, Delhivery, and Glenmark Pharmaceuticals today; check all the key details here

10 pharma firms launch semaglutide in India; Nomura sees ₹12k-cr mkt

Companies including Dr. Reddy's Laboratories, Sun Pharma, Zydus Lifesciences, Natco Pharma, Alkem Laboratories, and Torrent Pharmaceuticals have developed their own formulations

Nifty Pharma index hits 52-week high; Ipca, Aurobindo rally up to 4%

In the past one month, the Nifty Pharma index has rallied 4.5 per cent, as against 7.8 per cent decline in the benchmark Nifty 50.

Glenmark to launch generic sodium phosphates injection in US in April 2026

Glenmark Pharmaceuticals on Friday said its US-based unit is gearing up to introduce a generic sodium phosphates injection in the American market. The Mumbai-based drug firm said its product is therapeutically equivalent to Hosira Inc's reference listed drug. Glenmark will begin distribution of the injection in the US market in April 2026, it said in a regulatory filing. According to IQVIA, sales data for the 12-month period ending December 2025, the Sodium Phosphates Injection USP single-dose vials saw annual sales of around USD 66.8 million. Shares of the company were trading 0.82 per cent up at Rs 2,144.50 apiece on BSE.

Further downside ahead for Nifty? Here's today's outlook and top picks

Ajit Mishra of Religare Broking recommended Glenmark Pharmaceuticals, TVS Motor Company, and Power Finance Corporation for Thursday's session

Voda Idea, DLF, RBL Bank among 18 F&O stocks to attract 15% higher margin

The NSE to levy 15% additional margin on equity derivatives in which top 10 clients account for more than 20% MWPL from March F&O series onwards; withdraws additional margin on Gold, Silver futures.